Polymer-bound camptothecin: initial biodistribution and antitumour activity studies

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

P. Vasey, Stan B. Kaye, Rachel Morrison et al. · PubMed · 1999 · 691 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts

Beppino C. Giovanella, John S. Stehlin, Monroe E. Wall et al. · Science · 1989 · 647 citations

Medicine, Oncology, Pharmacology +15

On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex

Robert Hertzberg, Mary Jo Caranfa, Sidney M. Hecht · Biochemistry · 1989 · 552 citations

Medicine, Biochemistry, Pharmacology +10

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

William D. Kingsbury, Jeffrey C. Boehm, Dalia R. Jakas et al. · Journal of Medicinal Chemistry · 1991 · 516 citations

Medicine, Medicinal Chemistry, Pharmacology +10

DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues.

Y H Hsiang, Leroy F. Liu, Monroe E. Wall et al. · PubMed · 1989 · 341 citations

Medicine, Oncology, Pharmacology +13